Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1941 (ipragliflozin) + metformin in Asian T2DM
NCT01505426Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ASP1941 group with placebo group (2 arms). Primary endpoint: Change in HbA1c at 24 weeks. Started Nov 2011; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01505426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505426.